# psoriasis - deepseek-v4-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 7
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 33478
- Completion tokens: 15992
- Reasoning tokens: 0
- Total tokens: 49470
- API requests reported: 3
- Elapsed seconds: 120.68
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1150.303
- Question handoff seconds: 1163.566
- Final benchmark system: E2seq; file rank 5/5; original repeat 7; model vendor: DeepSeek

---
# Multidimensional Interpretation of Psoriasis Lesional Skin Transcriptomic Data

## 1. Overall Biological Interpretation

The dataset comprises 100 selected genes (90 upregulated, 10 downregulated) with extraordinarily strong statistical signals—all 100 genes pass FDR ≤ 0.01, with the majority having FDR values below 1e-60. This is a highly robust differential expression signature in psoriatic lesional skin versus normal control skin.

The dominant biological themes converge on three interrelated axes:

**First**, a massive **keratinocyte differentiation/epidermal barrier program** is activated, evidenced by coordinated upregulation of cornified envelope components (SPRR2A-F, SPRR3, LCE3A, LCE3D, PI3), keratins (KRT6A), and epidermal proteases (KLK13, TMPRSS11D, PRSS27). This reflects the hyperproliferative, aberrantly differentiated keratinocyte phenotype characteristic of psoriatic plaques.

**Second**, a **strong IL-17/IL-36-driven inflammatory axis** is evident through upregulation of IL36A, IL36G, IL19, IL20, IL26, IL36RN, IRAK2, and CXCL13. The IL-36 family members show the highest fold changes in the dataset (IL36A log2FC = 11.37), consistent with the established role of IL-36 signaling in psoriasis pathogenesis.

**Third**, an **antimicrobial/innate immune response program** is prominently activated, including S100 proteins (S100A7, S100A7A, S100A8, S100A12), beta-defensins (DEFB4A, DEFB4B, DEFB103A, DEFB103B), and PI3/elafin. These genes are classic psoriasis markers and reflect the disrupted epidermal antimicrobial barrier.

The downregulated genes (BTC, CYP2W1, UGT3A2, WAKMAR1, SAPCD1, and several uncharacterized loci) are fewer but may indicate loss of normal epidermal differentiation markers or metabolic functions. Notably, BTC (betacellulin, an EGFR ligand) downregulation (log2FC = -4.30) is interesting given the known involvement of EGFR signaling in epidermal homeostasis.

---

## 2. Core Biological Programs

### Program 1: IL-36/IL-17-Driven Inflammatory Signaling
- **Direction**: Upregulated
- **Major supporting genes**: IL36A (log2FC = 11.37), IL36G (5.68), IL19 (7.58), IL20 (5.67), IL26 (4.36), IL36RN (3.01), IRAK2 (2.08), ZC3H12A (3.85), TNIP3 (7.28)
- **Standardized pathway**: KEGG IL-17 signaling pathway; Reactome Interleukin-36 pathway (R-HSA-9014826); Reactome Interleukin-20 family signaling (R-HSA-8854691)
- **Explanation**: The coordinated upregulation of IL-36 agonists (IL36A, IL36G) alongside their receptor antagonist (IL36RN) indicates an active IL-36 axis with attempted negative feedback. IL36RN is a direct binding partner of IL1RL2 and prevents association with IL1RAP (STRING confidence 0.999 and 0.854, respectively). The concurrent upregulation of IL-19, IL-20, and IL-26—all IL-10 family cytokines with known roles in keratinocyte proliferation and inflammation—reinforces the Th17/IL-17-associated cytokine milieu. IRAK2 is a proximal TLR/IL-1R signaling adaptor, and TNIP3 (ABIN-3) is an NF-κB inhibitor, suggesting both activation and feedback regulation of inflammatory signaling.
- **Evidence strength**: Strong. Multiple independent genes converge on the same pathway, and the IL-36/IL-17 axis is well-established in psoriasis literature. However, this is a single-cohort observation; external cohort validation was not performed.
- **Limitations**: IL36RN upregulation alongside IL36A/IL36G could represent compensatory antagonism rather than pure pathway activation; the net functional outcome requires functional validation.

### Program 2: Epidermal Differentiation and Cornified Envelope Formation
- **Direction**: Upregulated
- **Major supporting genes**: SPRR2A (7.31), SPRR2B (6.38), SPRR2D (5.92), SPRR2E (3.99), SPRR2F (7.22), SPRR2G (4.75), SPRR3 (7.18), LCE3A (8.30), LCE3D (5.31), PI3 (9.24), KRT6A (4.30), KLK13 (4.05), TMPRSS11D (7.75)
- **Standardized pathway**: Reactome Formation of the cornified envelope (R-HSA-6809371)
- **Explanation**: The small proline-rich proteins (SPRRs) and late cornified envelope (LCE) proteins are structural components of the cornified envelope, a hallmark of terminal keratinocyte differentiation. Their massive upregulation (multiple genes with log2FC > 5) indicates aberrant epidermal differentiation—specifically, an accelerated or dysregulated cornification program. KRT6A is a hyperproliferation-associated keratin. KLK13 and TMPRSS11D are epidermal proteases involved in desquamation and barrier processing. STRING network evidence shows dense connectivity among SPRR2B, SPRR2D, SPRR2E, SPRR2F, LCE3A, and LCE3D, supporting their co-regulation as a functional module.
- **Evidence strength**: Strong. Multiple genes with extreme fold changes and STRING network connectivity support this as a coherent module.
- **Limitations**: Cornified envelope genes are also upregulated in other hyperproliferative epidermal conditions (e.g., wound healing, atopic dermatitis), so this program is not psoriasis-specific without additional context.

### Program 3: Antimicrobial Peptide and S100 Alarmin Response
- **Direction**: Upregulated
- **Major supporting genes**: S100A7 (7.09), S100A7A (9.83), S100A8 (7.73), S100A12 (8.33), DEFB4A (11.18), DEFB4B (11.03), DEFB103A (5.76), DEFB103B (5.75), PI3 (9.24)
- **Standardized pathway**: GO Antimicrobial humoral response (GO:0019730); KEGG Staphylococcus aureus infection
- **Explanation**: The S100 proteins (psoriasin/S100A7 and calgranulins S100A8/S100A12) are alarmins with antimicrobial and chemotactic functions. Beta-defensins (DEFB4A/B, DEFB103A/B) are antimicrobial peptides that also act as chemoattractants and can activate dendritic cells. PI3/elafin is a protease inhibitor with antimicrobial properties. The coordinated upregulation of these genes indicates an activated innate antimicrobial barrier, a well-documented feature of psoriatic epidermis. STRING evidence shows S100A7 connectivity with FABP5, S100A12, S100A7A, SERPINB3, and SERPINB4, suggesting a functional S100-alarmin cluster.
- **Evidence strength**: Strong. Multiple independent gene families (S100, defensins, elafin) converge on the same functional theme.
- **Limitations**: These genes are also induced in bacterial skin infections and other inflammatory dermatoses; the specificity to psoriasis requires comparison with other inflammatory skin conditions.

### Program 4: Keratinocyte Hyperproliferation and Metabolic Reprogramming
- **Direction**: Upregulated (with select downregulated genes)
- **Major supporting genes**: RRM2 (2.72), CCNE1 (2.56), AKR1B10 (6.27), AKR1B15 (5.23), FABP5 (3.64), KYNU (4.42), SLC6A14 (4.47), GJB2 (4.42), GJB6 (3.02)
- **Standardized pathway**: KEGG Cell cycle; GO Epidermis development (GO:0008544)
- **Explanation**: RRM2 (ribonucleotide reductase subunit) and CCNE1 (cyclin E1) are cell-cycle regulators consistent with keratinocyte hyperproliferation. AKR1B10 and AKR1B15 are aldo-keto reductases involved in retinoid metabolism and lipid peroxidation detoxification; AKR1B10 is a known marker of psoriatic epidermis and is being explored as a drug target (e.g., epalrestat, PMID 39017606). FABP5 (epidermal fatty acid binding protein) supports lipid transport in hyperproliferative epidermis. KYNU (kynureninase) is involved in tryptophan metabolism, which feeds into the kynurenine pathway with immunomodulatory consequences. The downregulation of CYP2W1 and UGT3A2 (xenobiotic/drug metabolism enzymes) suggests altered metabolic capacity in lesional skin.
- **Evidence strength**: Moderate-to-strong. Multiple genes support proliferation and metabolic reprogramming, but the program is more heterogeneous than Programs 1–3.
- **Limitations**: Cell-cycle genes (RRM2, CCNE1) may reflect the increased proportion of proliferating basal keratinocytes rather than a specific signaling program; composition effects need to be considered.

### Program 5: Neutrophil Chemotaxis and Innate Immune Cell Recruitment
- **Direction**: Upregulated
- **Major supporting genes**: CXCR2 (2.70), CXCL13 (5.89), S100A8 (7.73), S100A12 (8.33), HPSE (2.92), HRH2 (3.27), PLA2G4D (4.61), PLA2G4E (2.47)
- **Standardized pathway**: KEGG Cytokine-cytokine receptor interaction; GO Response to lipopolysaccharide (GO:0032496)
- **Explanation**: CXCR2 is the receptor for neutrophil chemoattractants (CXCL1-3, CXCL5-8) and is upregulated on neutrophils and keratinocytes in psoriasis. S100A8/A12 are potent neutrophil chemoattractants. HPSE (heparanase) degrades extracellular matrix heparan sulfate, facilitating leukocyte infiltration. The phospholipases PLA2G4D and PLA2G4E generate arachidonic acid and lysophospholipids, precursors of pro-inflammatory eicosanoids. HRH2 (histamine H2 receptor) may modulate immune cell function. STRING evidence places GNAS as a hub connecting HRH2, PLA2G4D, and PLA2G4E, suggesting G-protein-coupled signaling coordination.
- **Evidence strength**: Moderate. The individual genes have strong statistical support, and the neutrophil-recruitment theme is well-established in psoriasis (Munro microabscesses), but the program is less densely interconnected than Programs 1–3.
- **Limitations**: CXCL13 is more typically associated with B-cell follicles; its upregulation may reflect lymphoid neogenesis in psoriatic skin, which is a distinct but related process.

---

## 3. Key Genes and Interaction Modules

### Module 1: IL-36 Signaling Hub (IL36A, IL36G, IL36RN)
- **Statistical direction**: All upregulated (IL36A log2FC = 11.37; IL36G = 5.68; IL36RN = 3.01)
- **Role in core programs**: Central to Program 1 (IL-36/IL-17 inflammatory axis)
- **Gene-gene relationships**: Direct physical interaction—IL36RN binds IL1RL2 and prevents IL1RAP association (STRING confidence 0.999 for IL36RN-IL1RL2). IL36A and IL36G are agonists for the same receptor complex. IL36RN is a pathway co-member and regulatory antagonist of IL36A/IL36G signaling.
- **Evidence types**: Direct input statistics; pathway evidence (Reactome Interleukin-36 pathway); protein interaction evidence (STRING); disease-association evidence (IL36RN loss-of-function mutations cause generalized pustular psoriasis).

### Module 2: Cornified Envelope Gene Cluster (SPRR2A-F, SPRR3, LCE3A, LCE3D, PI3)
- **Statistical direction**: All upregulated (log2FC range 3.99–9.24)
- **Role in core programs**: Core of Program 2 (epidermal differentiation)
- **Gene-gene relationships**: Pathway co-membership and co-expression—these genes are co-regulated during keratinocyte differentiation and share the same genomic loci (SPRR cluster on 1q21, LCE cluster on 1q21). STRING shows dense edges among SPRR2B, SPRR2D, SPRR2E, SPRR2F, LCE3A, LCE3D. No direct physical interaction is established; they are structural components that co-assemble into the cornified envelope, so the relationship is best described as **functional co-assembly** rather than direct physical interaction in the conventional protein-protein sense.
- **Evidence types**: Direct input statistics; pathway evidence (Reactome cornified envelope); network evidence (STRING); expression evidence (keratinocyte differentiation).

### Module 3: S100 Alarmin Cluster (S100A7, S100A7A, S100A8, S100A12)
- **Statistical direction**: All upregulated (log2FC range 7.09–9.83)
- **Role in core programs**: Core of Program 3 (antimicrobial response)
- **Gene-gene relationships**: Co-expression and pathway co-membership. STRING shows S100A7 connecting to FABP5, S100A12, S100A7A, SERPINB3, SERPINB4. S100 proteins can form heterodimers (e.g., S100A8/S100A9), but S100A8/S100A12 interactions are less well-characterized. The relationship among these S100 genes is primarily **co-regulation** within the epidermal differentiation complex and shared alarmin function.
- **Evidence types**: Direct input statistics; pathway evidence (antimicrobial humoral response); network evidence (STRING); disease-association evidence (S100A7/psoriasin is a classic psoriasis marker).

### Gene 4: AKR1B10
- **Statistical direction**: Upregulated (log2FC = 6.27)
- **Role in core programs**: Program 4 (metabolic reprogramming); also contributes to inflammatory signaling through retinoid metabolism
- **Gene-gene relationships**: AKR1B15 is a pathway co-member (same enzyme family, adjacent genomic locus). No direct physical interaction is established with other selected genes.
- **Evidence types**: Direct input statistics; disease-association evidence (AKR1B10 is elevated in psoriatic epidermis); drug evidence (epalrestat targets AKR1B10, PMID 39017606, though this is in the context of non-small cell lung cancer, not psoriasis—the drug evidence does not constitute psoriasis therapeutic efficacy).

### Gene 5: KYNU (Kynureninase)
- **Statistical direction**: Upregulated (log2FC = 4.42)
- **Role in core programs**: Program 4 (metabolic reprogramming); kynurenine pathway generates immunomodulatory metabolites
- **Gene-gene relationships**: Indirect/putative—KYNU operates in the tryptophan-kynurenine pathway, which intersects with inflammatory signaling through aryl hydrocarbon receptor (AhR) activation. No direct interaction with other selected genes is documented.
- **Evidence types**: Direct input statistics; pathway evidence (tryptophan metabolism); limited disease-association evidence in psoriasis.

### Gene 6: CXCR2
- **Statistical direction**: Upregulated (log2FC = 2.70)
- **Role in core programs**: Program 5 (neutrophil chemotaxis)
- **Gene-gene relationships**: Pathway co-membership with S100A8/A12 (which signal through TLR4, not CXCR2, so the relationship is indirect). CXCR2 is the receptor for neutrophil chemoattractants; S100A8/A12 recruit neutrophils through a distinct mechanism.
- **Evidence types**: Direct input statistics; disease-association evidence (neutrophil infiltration is a hallmark of psoriasis); limited drug evidence (CXCR2 antagonists have been explored in inflammatory diseases).

### Gene 7: HPSE (Heparanase)
- **Statistical direction**: Upregulated (log2FC = 2.92)
- **Role in core programs**: Program 5 (immune cell recruitment); also relevant to Program 4 (ECM remodeling)
- **Gene-gene relationships**: Indirect—HPSE degrades heparan sulfate, releasing growth factors and chemokines. It may functionally interact with the broader inflammatory milieu but has no documented direct interaction with other selected genes.
- **Evidence types**: Direct input statistics; limited disease-association evidence in psoriasis.

### Gene 8: CD274 (PD-L1)
- **Statistical direction**: Upregulated (log2FC = 3.44)
- **Role in core programs**: Not central to the five core programs but relevant to immune regulation in psoriatic skin
- **Gene-gene relationships**: Indirect/regulatory—CD274 provides inhibitory signals to T cells. Its upregulation may represent a feedback mechanism to limit T-cell-mediated inflammation.
- **Evidence types**: Direct input statistics; disease-association evidence (immune checkpoint expression in psoriatic skin); literature evidence (immunotherapy targeting CD274, PMID 38354028, though in oncology context).

### Gene 9: WNT5A
- **Statistical direction**: Upregulated (log2FC = 2.53)
- **Role in core programs**: Program 4 (keratinocyte proliferation); WNT5A is a non-canonical WNT ligand involved in epidermal homeostasis
- **Gene-gene relationships**: Indirect/putative—WNT5A signaling intersects with inflammatory pathways but has no documented direct interaction with other selected genes.
- **Evidence types**: Direct input statistics; disease-association evidence (WNT signaling dysregulation in psoriasis).

### Gene 10: GJB2 and GJB6 (Connexins 26 and 30)
- **Statistical direction**: Both upregulated (GJB2 log2FC = 4.42; GJB6 = 3.02)
- **Role in core programs**: Program 4 (keratinocyte proliferation/differentiation); gap junction communication is critical for epidermal homeostasis
- **Gene-gene relationships**: Pathway co-membership—connexins form gap junctions; GJB2 and GJB6 can form heteromeric channels. This represents **functional interaction** (gap junction formation) but requires experimental evidence for direct physical interaction in psoriatic keratinocytes.
- **Evidence types**: Direct input statistics; expression evidence (connexin dysregulation in hyperproliferative epidermis).

---

## 4. Validation Priorities

### Priority 1: IL-36 Axis Functional Validation
- **Classification**: Mechanistic hypothesis
- **Why it deserves prioritization**: IL36A and IL36G show the highest fold changes in the dataset (log2FC = 11.37 and 5.68, respectively), and the IL-36 pathway is central to psoriasis pathogenesis. The concurrent upregulation of IL36RN (the antagonist) suggests a dynamic regulatory balance that needs functional dissection.
- **Current dataset evidence**: Strong statistical support for IL36A, IL36G, IL36RN, IRAK2 upregulation.
- **External evidence**: IL36RN loss-of-function mutations cause generalized pustular psoriasis (genetic evidence); IL-36 blockade is being explored therapeutically (drug evidence). Reactome and STRING confirm the IL-36 signaling architecture.
- **Next step**: Knockdown or neutralization of IL-36 in psoriatic keratinocyte organoids or mouse models; measure downstream IL-17/IL-23 responses. Alternatively, quantify IL-36 agonist/antagonist protein ratios in psoriatic lesions.
- **Conclusion status**: **Supported hypothesis**—the statistical evidence is strong, and external genetic evidence supports IL-36 involvement, but causal demonstration in this specific cohort requires functional validation.

### Priority 2: Cornified Envelope Gene Module as a Psoriasis-Specific Signature
- **Classification**: Biomarker
- **Why it deserves prioritization**: The SPRR/LCE module shows extreme fold changes and may serve as a robust, quantifiable biomarker of lesional skin. Distinguishing psoriasis-specific from general hyperproliferative signatures would enhance diagnostic specificity.
- **Current dataset evidence**: Multiple SPRR and LCE genes with log2FC > 4 and FDR < 1e-60.
- **External evidence**: These genes are well-characterized components of the epidermal differentiation complex; LCE3B/LCE3C deletions are psoriasis risk factors (GWAS evidence). However, SPRR/LCE genes are also induced in wound healing and other inflammatory dermatoses, so specificity needs testing.
- **Next step**: Compare SPRR/LCE expression in psoriasis versus atopic dermatitis, lichen planus, and wound healing samples; assess whether the SPRR2/LCE module distinguishes psoriasis from other inflammatory skin diseases.
- **Conclusion status**: **Exploratory hypothesis** for psoriasis specificity; **established evidence** for epidermal differentiation activation.

### Priority 3: S100/Defensin Antimicrobial Program as a Therapeutic Target
- **Classification**: Therapeutic target
- **Why it deserves prioritization**: The S100 and defensin genes show extreme upregulation and are implicated in amplifying inflammation through neutrophil recruitment and TLR4 activation. Targeting this program could modulate both antimicrobial defense and inflammation.
- **Current dataset evidence**: S100A7 (7.09), S100A7A (9.83), S100A8 (7.73), S100A12 (8.33), DEFB4A (11.18), DEFB4B (11.03) all strongly upregulated.
- **External evidence**: S100A8/A9 (calprotectin) is a clinical biomarker of disease activity in inflammatory bowel disease and is elevated in psoriasis. However, no approved psoriasis therapy directly targets S100 proteins, and the antimicrobial function suggests caution in complete blockade.
- **Next step**: Test whether S100A8/A12 neutralization reduces neutrophil recruitment and inflammation in psoriatic skin models; evaluate whether S100 levels track treatment response in longitudinal cohorts.
- **Conclusion status**: **Exploratory hypothesis**—the expression evidence is strong, but therapeutic targeting requires substantial additional validation.

### Priority 4: AKR1B10 Metabolic Axis Validation
- **Classification**: Mechanistic hypothesis
- **Why it deserves prioritization**: AKR1B10 shows one of the highest fold changes (log2FC = 6.27) and is an enzyme with druggable potential (epalrestat, PMID 39017606). Understanding its role in psoriatic keratinocyte metabolism could reveal new therapeutic angles.
- **Current dataset evidence**: AKR1B10 and AKR1B15 both strongly upregulated.
- **External evidence**: AKR1B10 is established as elevated in psoriatic epidermis; it metabolizes retinaldehyde and lipid peroxidation products. Drug evidence exists for epalrestat in cancer contexts but not psoriasis.
- **Next step**: Inhibit AKR1B10 in psoriatic keratinocyte models; assess effects on retinoid signaling, oxidative stress responses, and keratinocyte proliferation. Measure retinaldehyde and lipid peroxidation levels in lesional versus normal skin.
- **Conclusion status**: **Supported hypothesis** for involvement in psoriasis; **insufficient evidence** for therapeutic targeting.

### Priority 5: Cell-Composition Confounding Check
- **Classification**: Confounding or composition check
- **Why it deserves prioritization**: The transcriptomic signature likely reflects not only keratinocyte-intrinsic changes but also the altered cellular composition of psoriatic lesions (increased neutrophils, T cells, dendritic cells; altered keratinocyte differentiation state). Disentangling cell-intrinsic from composition-driven signals is essential for accurate interpretation.
- **Current dataset evidence**: Upregulation of neutrophil chemoattractants (CXCR2, S100A8/A12) and T-cell-associated genes (CXCL13, PRKCQ) suggests immune cell infiltration contributes to the bulk signal.
- **External evidence**: Single-cell RNA-seq studies of psoriasis have demonstrated distinct keratinocyte, T-cell, and myeloid cell populations with specialized transcriptional programs.
- **Next step**: Perform single-cell RNA-seq or deconvolution analysis (e.g., CIBERSORTx, MuSiC) on the same samples to determine which genes are keratinocyte-intrinsic versus immune-cell-derived. Validate key findings (IL-36, SPRR, S100) by immunohistochemistry or in situ hybridization.
- **Conclusion status**: **Established evidence** that composition matters; the specific contribution to each gene's signal requires validation.

---

## 5. Evidence Grounding

### Direct Evidence from Input Dataset
The uploaded statistics provide direct evidence for differential expression of 100 genes (90 up, 10 down) with all genes passing FDR ≤ 0.01. This is the only direct statistical evidence for this cohort. The extreme significance levels (many FDR values < 1e-60) indicate robust detection, but do not by themselves establish biological significance or disease causality.

### Pathway/Ontology Evidence
Reactome, KEGG, and GO annotations support the biological programs described: Reactome Formation of the cornified envelope (12 genes), Interleukin-36 pathway (IL36RN), Interleukin-20 family signaling (IL19); KEGG IL-17 signaling, Cytokine-cytokine receptor interaction, Staphylococcus aureus infection; GO Response to lipopolysaccharide, Epidermis development, Antimicrobial humoral response. These are contextual annotations, not computed enrichment statistics from this dataset.

### Protein Interaction/Regulatory Evidence
STRING provides network evidence for several modules: SPRR/LCE connectivity (8 genes), S100A7 cluster (5 genes), IL-36 receptor complex (IL36A, IL36G, IL36RN with IL1RAP), and GNAS-linked signaling (HRH2, PLA2G4D, PLA2G4E). These interactions are predicted or curated from multiple evidence types and should be treated as network hypotheses, not direct physical interaction measurements in this dataset. Regulatory evidence from TRRUST covers only 17/100 genes, limiting regulatory network inference.

### Disease-Association Evidence
GWAS records were retrieved for 100/100 selected genes, but this does not mean all are psoriasis-associated; it reflects database coverage. Established psoriasis genetics include IL36RN (pustular psoriasis), LCE3B/LCE3C deletions, and HLA region genes. Most other genes have disease associations in other contexts (e.g., AKR1B10 in cancer, CXCL13 in autoimmune diseases).

### Expression/Tissue-Specific Evidence
GTEx (83/100) and Human Protein Atlas (76/100) provide expression context. Many selected genes show skin-enriched expression (SPRR, LCE, S100, defensins), consistent with their roles in epidermal biology. This supports the tissue relevance of the findings.

### Drug/Therapeutic Evidence
41/100 genes have drug-related records (OpenTargets, ChEMBL, ClinicalTrials). Notable examples: AKR1B10 (epalrestat), CXCR2 antagonists, CD274 (PD-L1) checkpoint inhibitors, IL-36 pathway modulators. **Critical caveat**: Drug existence does not constitute evidence of therapeutic efficacy in psoriasis. For example, epalrestat's reported activity is in non-small cell lung cancer (PMID 39017606), not psoriasis.

### Literature Evidence
The retrieved literature (669 PubMed articles, 848 Europe PMC articles) includes psoriasis-relevant records (e.g., PMID 40560938 on psoriasis biomarker identification) and gene-specific studies. However, the literature search was broad, and most retrieved articles pertain to other diseases. Literature support should be treated as contextual, not as independent replication.

### Independence Assessment
The evidence sources are **not fully independent**. Pathway annotations (Reactome, KEGG, GO) may share underlying literature. STRING integrates multiple data types including literature co-occurrence. GWAS and ClinVar records may derive from overlapping studies. The strongest claim to independence comes from the combination of (a) direct input statistics, (b) established genetic evidence (e.g., IL36RN mutations in pustular psoriasis), and (c) single-cell or functional studies—but such functional studies were not directly supplied in this analysis.

---

## 6. Limitations and Alternative Explanations

### Limitation 1: Cell-Composition Differences
Psoriatic lesional skin contains increased neutrophils, T cells, dendritic cells, and altered keratinocyte differentiation states compared to normal skin. Bulk RNA-seq reflects this compositional shift. Genes like CXCR2, CXCL13, and S100A8/A12 may be substantially derived from infiltrating immune cells rather than keratinocytes. **Investigation**: Single-cell RNA-seq, deconvolution, or immunohistochemistry to localize expression to specific cell types.

### Limitation 2: Disease Severity and Lesion Selection
The dataset compares lesional versus normal skin without specifying disease severity, lesion chronicity (early versus established plaque), or body site. Psoriasis is heterogeneous, and transcriptomic profiles vary with disease activity. **Investigation**: Stratify by PASI score, lesion duration, or body site; include non-lesional skin as an additional comparator to distinguish disease-specific from lesion-specific changes.

### Limitation 3: Treatment Exposure
The dataset does not specify whether patients were treatment-naive or had prior/current therapy. Topical corticosteroids, vitamin D analogs, biologics, and systemic immunosuppressants profoundly alter the psoriatic transcriptome. **Investigation**: Document treatment history; ideally validate in treatment-naive cohorts.

### Limitation 4: Association-Versus-Causation Ambiguity
The differential expression results establish associations, not causal relationships. For example, IL36A upregulation could be a cause of inflammation, a consequence of keratinocyte stress, or both. The concurrent upregulation of IL36RN (antagonist) illustrates the dynamic regulatory context. **Investigation**: Functional perturbation studies (knockdown, overexpression, neutralizing antibodies) in relevant models.

### Limitation 5: Platform and Batch Effects
The dataset does not specify the sequencing platform, sample processing, or batch structure. Technical variation could influence fold changes, particularly for extreme values (log2FC > 10 for IL36A and DEFB4A/B). **Investigation**: Confirm key findings by qPCR or orthogonal methods; assess batch effects if raw data are available.

---

## Summary

This transcriptomic analysis of psoriatic lesional skin reveals a highly robust (all 100 genes FDR ≤ 0.01) signature dominated by three interconnected programs: (1) IL-36/IL-17-driven inflammation, (2) aberrant epidermal differentiation with cornified envelope activation, and (3) antimicrobial/alarmin responses. The extreme fold changes in IL36A (11.37), DEFB4A (11.18), DEFB4B (11.03), and S100A7A (9.83) highlight the intensity of the lesional inflammatory and barrier disruption phenotype. These findings are consistent with established psoriasis biology, but external cohort validation was not performed, and the causal relationships and cell-type specificity of these signals require functional validation. The most promising directions for further research include functional dissection of the IL-36 axis, evaluation of the SPRR/LCE module as a psoriasis-specific biomarker, and single-cell resolution of the cell-type contributions to this signature.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=7, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: deepseek / deepseek-v4-flash.

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 91/100 selected items (records returned); cbioportal 91/100 selected items (records returned); chembl 11/100 selected items (partially returned; some queries failed); civic 4/100 selected items (records returned); clinicaltrials 40/100 selected items (records returned); clinvar 90/100 selected items (records returned); ensembl 44/100 selected items (partially returned; some queries failed); europepmc 848 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 83/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 76/100 selected items (records returned); humanbase 100/100 selected items (records returned); intact 79/100 selected items (records returned); mygene 100/100 selected items (records returned); omnipath 36/100 selected items (records returned); opentargets 90/100 selected items (records returned); pubmed 669 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 80/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 2/100 selected items (records returned); hmdb 25/100 selected items (records returned); string 78/100 selected items (records returned); trrust 17/100 selected items (records returned)
